US FDA Panel Rejects Pfizer's Broad COVID Booster Plan But Backs Narrower Authorization For Third Vaccine Shot

 
• By Sue Sutter

Advisory committee meeting reflected internal tensions among FDA staff on need for boosters and adequacy of the data; mRNA vaccine Comirnaty should be authorized for a third dose in populations at high risk for severe disease or exposure, panel says after overwhelmingly rejecting Pfizer's bid for booster approval in the 16-and-older population. 

Jaws of shark
A second, hastily written voting question on boosters allowed FDA leaders and the Biden Administration to snatch victory from the jaws of defeat. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers